Clozapine: an historical view and current use in treatment resistant schizophrenia
Keywords:
Clozapine, Resistant schizophrenia, Neutropenia, AgranulocytosisAbstract
Clozapine was developed as the fi rst atypical antipsychotic with activity against both the positive and negativesymptoms of schizophrenia. Following its partial withdrawal over agranulocyrosis, it was reintroduced in market(in Spain, 1993) in response to have at one’s disposal alternative in treatment resistant schizophrenia. Clozapinerepresents the current “gold standard” in the treatment resistant schizophrenia and severe psychotic disorders.The low risk of agranulocytosis and death associated with the use of clozapine, by means of strict hematologicsurveillance program, is offset by the clinical benefi ts of the drug in the treatment of schizophrenia and otherneurological disorders.Downloads
References
Bobon DP, Janssen PAJ, Bobon D, eds. The Neuroleptics: Modern Problems of Pharmacopsychiatry, vol.5; Basel, Switzerland: Karger, 1970
Stille G, Hippius H. Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmacologischen und klinischen Befunden mit Clozapin). Pharmakopsychiatrie 1971; 4: 182-191
Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psychiatr Scand 1977; 56: 241-248
Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group. Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796
Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V et al. The risks and benefit of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377-384
Cervera S, Seva A. Esquizofrenia resistente al tratamiento farmacológico. Actas Españolas de Psiquiatria 2006; 34 (1): 48-54
Barnes TR, McEvedy CJ. Pharmacological treatment strategies in the non-responsive schizophrenic patient. Int J Clin Psychopharmacol 1996 ; 11 (suppl. 2): 67-71
Juárez-Reyes MG, Shumway M, Battle C, Bachetti P, Hansen MS, Hargreaves WA. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 1995; 46: 801-806
Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-549
Goldstein JM. Gender differences in the course of schizophrenia. Am J Psychiatry 1988; 145: 684-689
Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcomes in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975-983
Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patient with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-526.
Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM et al. Clozapine, diabetes mellitus, hyperlipidemia and cardiovascular risk and mortality: result of a 10-year naturalistic study. J Clin Psychiatry 2005; 66: 1116-1121
Buckley P, Bartell J, Donenbirth K, Lee S; Toriqoe F, Schultz SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995; 23: 607-611
Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-190
Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-677
Pickard D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49: 345-353
Lindenmayer JP; Grochowsky S, Mabugat L. Clozapine effects on positive and negative symptoms: a six month trial in treatment-refractory schizophrenia. J Clin Psychopharmacol 1994; 14: 201-204
Hagger C, Buckley P, Kenny JT, Friedman L, Ubogv D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702-712
McGurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999; 60 (suppl. 12): 24-29
Ranjan R, Meltzer HY. Acute and long term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996; 40: 253-258
Naber D. Optimizing Clozapine Treatment. J Clin Psychiatry 1999; 60 (suppl. 12): 35-38
Tiihönen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JPA, Volavka J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalizacion due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ, doi:10-1136/bmj.38881.382755.2F (published 6 July 2006)
Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine induced-agranulocytosis: incidence and risk factor in the United States. N Eng J Med 1993; 329: 162-167
Lambertenghi Deliliers G. Blood dyscrasias in clozapina-treated patients in Italy. Haematologica 2000; 85(3): 233-237
Alphs LD, Anand R. Clozapine : The Commitment to Patient Safety. J Clin Psychiatry 1999; 60 (suppl. 12): 39-42
Esposito D, Rouillon F, Limosin F. Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol 2005; 60: 759-764
Santamaría Ruiz B. Programa de seguimiento de clozapina; Madrid:Tesis doctoral, 1999
Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side effects. Br J Psychiatry 1992; 160 (suppl. 17): 54-59.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
